In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial.
Implications of Mutation Profiling in Myeloid Malignancies—PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.
Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.
Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.
A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI.
The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.